Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Post-marketing Study to Monitor the Safety of Beijing Tiantan Biological's Influenza Virus Vaccine Administered in Chinese Subjects Aged 60 Years or Older

NCT01906593 is registered in ClinicalTrials.gov with Centers for Disease Control and Prevention, China as lead sponsor.

NCT NCT01906593
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01906593 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Post-marketing Study to Monitor the Safety of Beijing Tiantan Biological's Influenza Virus Vaccine Administered in Chinese Subjects Aged 60 Years or Older
Lead sponsor
Centers for Disease Control and Prevention, China
Phase
Observational
Overall status
Completed
Start date
June 30, 2013
Completion date
July 31, 2013
Enrollment
536,812 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, vaccination adverse event